The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy.

Nakamura, Takumi; Tanaka, Natsuha; Higuma, N; Kazama, Tatsuo; Kobayashi, I; Yokota, Soichiro

doi:10.1681/asn.v7112434

Cited by 23 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches

Costantino¹,

Rastelli²,

Vianello

et al. 1999

Med. Res. Rev.

147

View full text Add to dashboard Cite

Despite recent advances both in the chemistry and molecular pharmacology of antidiabetic drugs, diabetes still remains a life‐threatening disease, which tends to spread all over the world. The clinical profile of diabetic subjects is often worsened by the presence of several long‐term complications, namely neuropathy, nephropathy, retinopathy, and cataract. Several attempts have been made to prevent or at least to delay them. The most relevant are reported in this review, including the development of compounds acting as aldose reductase inhibitors, anti‐advanced glycation end‐product drugs, free radical scavengers, vasoactive agents, essential fatty acid supplementation, and neurotropic growth factors. © 1999 John Wiley & Sons, Inc. Med Res Rev, 19, No. 1, 3–23, 1999.

show abstract

Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches

Costantino¹,

Rastelli²,

Vianello

et al. 1999

Med. Res. Rev.

147

View full text Add to dashboard Cite

show abstract

Metals affect the structure and activity of human plasminogen activator inhibitor‐1. I. Modulation of stability and protease inhibition

et al. 2011

View full text Add to dashboard Cite

Human plasminogen activator inhibitor type 1 (PAI-1) is a serine protease inhibitor with a metastable active conformation. Under physiological conditions, half of the inhibitor transitions to a latent state within 1-2 h. The interaction between PAI-1 and the plasma protein vitronectin prolongs this active lifespan by~50%. Previously, our group demonstrated that PAI-1 binds to resins using immobilized metal affinity chromatography (Day, U.S. Pat. 7,015,021 B2, March 21, 2006). In this study, the effect of these metals on function and stability was investigated by measuring the rate of the transition from the active to latent conformation. All metals tested showed effects on stability, with the majority falling into one of two types depending on their effects. The first type of metal, which includes magnesium, calcium and manganese, invoked a slight stabilization of the active conformation of PAI-1. A second category of metals, including cobalt, nickel and copper, showed the opposite effects and a unique vitronectin-dependent modulation of PAI-1 stability. This second group of metals significantly destabilized PAI-1, although the addition of vitronectin in conjunction with these metals resulted in a marked stabilization and slower conversion to the latent conformation. In the presence of copper and vitronectin, the halflife of active PAI-1 was extended to 3 h, compared to a half-life of only~30 min with copper alone. Nickel had the largest effect, reducing the half-life to~5 min. Together, these data demonstrate a heretofore-unknown role for metals in modulating PAI-1 stability.

show abstract

Coagulation and Hemostasis in Diabetic Nephropathy

Roelofs

2018

Diabetic Nephropathy

View full text Add to dashboard Cite

The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy.

Cited by 23 publications

References 0 publications

Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches

Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches

Metals affect the structure and activity of human plasminogen activator inhibitor‐1. I. Modulation of stability and protease inhibition

Coagulation and Hemostasis in Diabetic Nephropathy

Contact Info

Product

Resources

About